Technology Bundle ID: TAB-2504

Diagnostic Test and Therapeutic Target for Sjogren's Syndrome

Request More Info
Licensing Contact:
Primary Inventors: 
John Chiorini (NIDCR)
Co-Inventors: 
Hongen Yin (NIDCR), Melodie Weller (NIDCR)
Therapeutic Area: 
Immunology
Application: 
Diagnostics
Development Status: 
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
  • In vivo data available (human)
Institute or Center: 
NIDCR

Sjögren's syndrome is an autoimmune disease that attacks salivary glands resulting in chronic dry mouth and dry eyes. Currently, there is no single diagnostic test to confirm the presence of Sjögren's. Physicians presently reach diagnosis after conducting a series of blood and functional tests for tear and salivary production. Diagnosis is further complicated as Sjögren's symptoms frequently mimic those of other autoimmune diseases (e.g., lupus, rheumatoid arthritis, etc.) and is often overlooked as dryness associated with medications being taken by the patient.

Researchers at NIDCR have identified overexpression of a growth factor, bone morphogenetic protein 6 (BMP6), in patients with Sjögren's. By detecting BMP6 expression and/or activity, this invention potentially presents a singular confirmation to diagnose those suffering and those at risk for developing Sjögren's. BMP6 also presents a potential therapeutic target for Sjögren's, a disease for which there is presently no cure.

Researchers have also discovered unique expression profiles for two other genes (XIST and MECP2) in male Sjögren's patients. Detecting aberrant expression and/or activity of these genes also offer a potential singular test for diagnosing Sjögren's in male subjects.

Applications:
  • Singular diagnostic test to diagnose Sjögren's
  • Therapeutic target to develop treatment for Sjögren's
Advantages:
  • Currently no single test available to diagnose Sjögren's
  • Currently there is no cure for Sjögren's; present palliative treatments only reduce symptoms (e.g., moisture replacement therapy for eyes and mouth, and systemic anti-inflammatory or immunosuppressive agents for more advanced forms of disease)

Patents

PCT Application PCT/US2013/061587
Filed on 2013-09-25
US Application 14/858,929
Filed on 2015-09-18
US Application 61/540,364
Filed on 2011-09-28
US Application 61/705,517
Filed on 2012-09-25
US Pat 10,864,285

Issued 2020-12-15
US Pat 9,833,519

Issued 2017-12-05

Publications

Dix DJ, et al.
PMID 8622925

Updated

Nov 21, 2012

Data Source: 
tts